FUJIFILM Biotechnologies, a prominent player in the contract development and manufacturing organization (CDMO) space, has unveiled ShunzymeX, an innovative precision purification technology aimed at enhancing the downstream processing of complex biologics. This cutting-edge technology will be showcased at the upcoming Festival of Biologics conference in San Diego, highlighting its potential to transform industry practices.
Streamlining the Purification Process
In collaboration with the University of Edinburgh, FUJIFILM Biotechnologies developed ShunzymeX to simplify the purification of complex biologics. The technology introduces a proprietary protease that facilitates the addition of an affinity tag to the target protein. This tag allows for purification using readily available affinity resins, significantly simplifying the process. Once purification is complete, the novel protease efficiently removes the tag, leaving the native protein unscathed.
Addressing Challenges in Traditional Methods
Traditional microbial downstream purification often presents significant hurdles due to the variability in size and sequence of microbial-expressed proteins. This variability can result in a lack of suitable affinity resins, leading to prolonged development times and compromised yields and purity. ShunzymeX addresses these challenges head-on, streamlining purification processes and ultimately reducing the time required for process development, thereby accelerating progress toward Good Manufacturing Practice (GMP) readiness.
Versatile and Scalable Technology
One of the standout features of ShunzymeX is its compatibility with various expression systems and its scalability directly to cGMP. This adaptability positions the technology as a valuable asset for biotech companies looking to enhance their purification capabilities. By integrating ShunzymeX into their workflows, organizations can expect to see a notable reduction in development timelines and improved outcomes.
Experience and Innovation
With over three decades of experience in microbial innovations, FUJIFILM Biotechnologies has a proven track record in advancing microbial technologies. John Stewart, senior vice president of Global Process Development, emphasized the company’s commitment to innovation, stating that ShunzymeX represents a significant step forward in facilitating faster commercialization for their clients.
Showcasing at the Festival of Biologics
The Festival of Biologics serves as an ideal platform to introduce ShunzymeX to industry stakeholders. Kenneth Holbourn, senior director and technical project leader, expressed excitement about presenting the technology. With over 2,000 attendees, the event will foster discussions on the latest advancements driving the sector forward. Holbourn’s session, titled “Accelerating and Streamlining Microbial Process Development with a Novel Technology,” will delve into how ShunzymeX can reshape purification processes.
Collaborative Efforts for Success
The partnership between FUJIFILM Biotechnologies and the University of Edinburgh, initiated in 2019, has been pivotal in bringing ShunzymeX to fruition. Supported by joint funding from UK Research and Innovation and Edinburgh Innovations, this collaboration has harnessed academic expertise to address critical challenges in biologics manufacturing. Professor Susan Rosser, the academic lead for this partnership, underscored the transformative nature of such collaborations, emphasizing the impact on making treatments and vaccines more accessible.
Conclusion
The introduction of ShunzymeX by FUJIFILM Biotechnologies marks a significant advancement in the purification of complex biologics. By simplifying the downstream processing and enhancing scalability, this technology promises to expedite the journey from development to market. As the biotech industry continues to evolve, innovations like ShunzymeX will play a crucial role in making biologic therapies more efficient and accessible for all.
- Key Takeaways:
- ShunzymeX simplifies the purification of complex biologics.
- The technology addresses challenges in traditional microbial purification methods.
- ShunzymeX is compatible with various expression systems and scalable to cGMP.
- Collaborative efforts with the University of Edinburgh have driven this innovation.
- The technology will be showcased at the Festival of Biologics, a key industry event.
Read more → www.pharmabiz.com